UK-based oncology technology developer Oxford Vacmedix (OVM) closed a £9m ($12.5m) series A round today featuring molecular diagnostics technology producer Cancer Rop and unnamed existing shareholders based in China.
Founded in 2012, Oxford Vacmedix has created a platform to develop cancer vaccines and diagnostic tools by exploiting recombinant overlapping peptides (ROP), which stimulate T cell immunity. T cells are a natural part of the human system and an important basis for immunotherapy.
OVM is based on research led by Shisong…